5 min
1 filesThe AACR Annual Meeting will be held from April 17 to 22, 2026, at the San Diego Convention Center in California.
According to official statistics from this year’s conference, a total of 104 Chinese biopharmaceutical companies will showcase more than 250 innovative drugs, along with related clinical and preclinical research findings.
Among the most prominent pipelines at this year’s AACR, antibody-drug conjugates (ADCs) continue to dominate, with as many as 92 ADC programs being presented. This highlights how China’s foundational technological capabilities in the ADC field have been successfully translated into a globally competitive advantage.
In addition, 66 precision-targeted small molecule drugs—covering challenging targets such as KRAS, PRMT5, WRN, and CDK—will be featured. Breakthrough data will also be presented across cutting-edge areas including radiopharmaceuticals, mRNA immunotherapies, bispecific biologics, and cell therapies.
Below is a curated list of pipelines from Chinese pharmaceutical companies that will be disclosed at the AACR Annual Meeting.
